Fewer HAE Attacks Evident With Takhzyro Use in Canadian Study

Fewer HAE Attacks Evident With Takhzyro Use in Canadian Study

309128

Fewer HAE Attacks Evident With Takhzyro Use in Canadian Study

Use of Takhzyro (lanadelumab) for at least six months led to fewer hereditary angioedema (HAE) attacks and treated attacks, a case review study from Canada reported. Three of its 12 patients went into complete remission, and all enjoyed a more comfortable social life, the investigators noted. The study, by researchers from several Canadian institutions, is titled “Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada,” and published in the journal Allergy, Asthma…

You must be logged in to read/download the full post.